WHO BioHub System

Technical Consultation

‘Approaches to handling Genetic Sequence Data for the future pandemic system’

19 November 2021
Agenda

- Opening remarks
- Introduction to the WHO BioHub System and its Guiding Principles
- Presentation of meeting objectives
- Moderated discussion
- Closing remarks
Opening remarks

Dr Catharina Boehme
WHO Chef de Cabinet

Dr Michael Ryan
Executive Director
WHO Health Emergencies Programme
Introduction to the WHO BioHub System and its Guiding Principles
WHO BioHub System: Concept & Elements

Countries
Voluntary sharing of biological materials

Sharing via SMTA 1*

WHO BioHub Facility

WHO BioHub System

Global Knowledge & Development of countermeasures

Allocation

Recipients
Qualified entities
Non-commercial use
Commercial use

Sharing via SMTA 2
Sharing via SMTA 3

Allocation Advisory Group
Prioritizes BMEPP** allocation

* Standard Material Transfer Agreement
** Biological materials with epidemic or pandemic potential
### Guiding Principles of the WHO BioHub System

<table>
<thead>
<tr>
<th>Principle</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A voluntary system for the global public health</td>
<td></td>
</tr>
<tr>
<td>Equity and fairness</td>
<td></td>
</tr>
<tr>
<td>Transparency</td>
<td></td>
</tr>
<tr>
<td>Acknowledgement and co-authorship</td>
<td></td>
</tr>
<tr>
<td>Consistency with applicable ethical regulations, norms, and standards</td>
<td></td>
</tr>
<tr>
<td>requirements</td>
<td></td>
</tr>
<tr>
<td>Timeliness</td>
<td></td>
</tr>
<tr>
<td>Collaboration &amp; Cooperation</td>
<td></td>
</tr>
<tr>
<td>Best practices for safety and security</td>
<td></td>
</tr>
<tr>
<td>Consistency with applicable law</td>
<td></td>
</tr>
<tr>
<td>Sustainability and maximal preservation</td>
<td></td>
</tr>
</tbody>
</table>

The full text of the Guiding Principles can be found at:  
[https://www.who.int/initiatives/who-biohub](https://www.who.int/initiatives/who-biohub)
Key Guiding Principles in focus for this thematic session

Timeliness

To enable an effective public health response, the end-to-end system from sample collection to shipping and generation of scientific information must function with urgency. Data and analyses will be made publicly available in a timely manner, while respecting all applicable WHO, international, and national regulations and standards, and communicated promptly to decision-makers in the affected countries as well as more broadly to all WHO Member States to support effective and timely response measures.
Key Guiding Principles in focus for this thematic session

Equity and fairness

Equity and fairness, as well as public health risk and need, will govern access to BMEPP contributed to the WHO BioHub System, and the research, data, and other materials resulting from the WHO BioHub System.
Key Guiding Principles in focus for this thematic session

Transparency

Terms and conditions with respect to the use of BMEPP, sequence data and information from the WHO BioHub System will be made publicly available, as will criteria to receive BMEPP.
Approach to developing the WHO BioHub System

- Stream 1: Pilot Testing
- Stream 2: System Design
WHO is working in accordance with WHA 74.7

WHO is aiming to:

- Serve the request from MS made in WHA74.7, Agenda item 17.3 31 May 2021
- Ensure availability of a pathogen sharing system that can be rapidly activated in the event of Disease X

Paragraph 9.15:

- work together with Member States, the medical and scientific community, and laboratory and surveillance networks,
- to promote early, safe, transparent and rapid sharing of samples and genetic sequence data of pathogens of pandemic and epidemic, or other high-risk, potential,
- taking into account relevant national and international laws, regulations, obligations and frameworks, including, as appropriate, the International Health Regulations (2005), the Convention on Biological Diversity and the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization and the Pandemic Influenza Preparedness Framework and
- the importance of ensuring rapid access to human pathogens for public health preparedness and response purposes;".

WHO BioHub System
Topics for technical consultations with stakeholders

**Research**
Handling research results and appropriate recognition of contributions

*Key (technical) stakeholders:*
Lab networks, scientists and biorepositories etc

**GSD**
Sharing of Genetic Sequence Data

*Key (technical) stakeholders:*
Legal experts and civil society and industry, other UN agencies, etc

**IPR**
Intellectual Property Rights

*Key (technical) stakeholders:*
Legal experts and civil society and industry, other UN agencies, etc

**Access to benefits arising from the sharing of BMEPP**
Difference between non-commercial and commercial benefits

*Key (technical) stakeholders:*
Legal experts esp. on Nagoya, civil society and industry involvement, etc

WHO BioHub System
WHO BioHub System: Concept & Elements

Countries
Voluntary sharing of biological materials

- Sharing via SMTA 1*

Sharing

WHO BioHub System
WHO BioHub Facility

- Allocation

Global Knowledge & Development of countermeasures

WHO BioHub System

Recipients
Qualified entities
Non-commercial use
Commercial use

Allocation Advisory Group
Prioritizes BMEPP** allocation

Sharing via SMTA 2
Sharing via SMTA 3

* Standard Material Transfer Agreement
** Biological materials with epidemic or pandemic potential
Meeting objectives

The consultation aims to:

- obtain input from various stakeholders to design the WHO BioHub System

- engage different stakeholder communities early on, in the design of the System, to ensure its smooth global functioning, to bring global benefits and to advance public health goals
Discussion

1. What do you consider to be the most important factors and considerations relating to GSD vis-à-vis the BioHub project?

2. What are your views on:
   • GSD generated from processing of BMEPP being made **publicly accessible** and
   • whether the **Provider of BMEPP** should be able to choose which type of databases categories to upload GSD in?

3. How can we address the **handling and use of BMEPP GSD** to promote fair and equitable sharing of public health benefits arising from its use?

The background paper for this thematic session can be found [here](#).
Thank you!

https://www.who.int/initiatives/who-biohub/

WHO Secretariat can be reached for any further inputs at: biohub@who.int